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Abstract
We have previously reported that Vivax Malaria Protein 001 (VMP001), a vaccine candidate based on the circumsporozoite
protein of Plasmodium vivax, is immunogenic in mice and rhesus monkeys in the presence of various adjuvants. In the
present study, we evaluated the immunogenicity and efficacy of VMP001 formulated with a TLR9 agonist in a water-in-oil
emulsion. Following immunization, the vaccine efficacy was assessed by challenging Aotus nancymaae monkeys with P.
vivax sporozoites. Monkeys from both the low- and high-dose vaccine groups generated strong humoral immune responses
to the vaccine (peak median titers of 291,622), and its subunits (peak median titers to the N-term, central repeat and C-term
regions of 22,188; 66,120 and 179,947, respectively). 66.7% of vaccinated monkeys demonstrated sterile protection
following challenge. Protection was associated with antibodies directed against the central repeat region. The protected
monkeys had a median anti-repeat titer of 97,841 compared to 14,822 in the non-protected monkeys. This is the first report
demonstrating P. vivax CSP vaccine-induced protection of Aotus monkeys challenged with P. vivax sporozoites.
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The range of Plasmodium vivax transmission spans 95 countries
putting 2.86 billion people at risk for this malaria parasite [1] and
causes an estimated 132–391 million infections each year [2]. In
addition to its widespread distribution, P. vivax also has the
propensity to form dormant hypnozoites in the liver, which
reactivate periodically and result in recurring relapse infections.
Currently, the only treatment for these intrahepatic hypnozoites is
the 8-aminoquinoline, primaquine (PQ), which is contraindicated
in a variable proportion of populations due to a risk of hemolysis in
individuals with G6PD deficiency [3] or during pregnancy. More
recently, Bennett and colleagues reported an association between
decreased activity of the CYP2D6 isoenzyme and reduced
metabolism of PQ resulting in treatment failure [4]. This further
reduces the pool of individuals who may be treated with PQ,
reinforcing the need to develop a vaccine to prevent P. vivax
malaria. However, resources for vivax research remain limited,
with only 5% of malaria funds specifically directed toward P.
vivax between 2007 and 2011 (PATH Malaria R&D Report,
2013). In addition, funding initiatives such as the U.S. govern-
ment’s President’s Malaria Initiative (PMI) have strictly limited
assistance, mostly to select countries in Africa, leaving little room
for funding vivax malaria control or research [5].
Due to the unpredictability of hypnozoite reactivations that
cause relapse infections, an intervention based on a preerythroc-
tyic stage antigen is even more imperative for P. vivax to prevent
primary infection and subsequent relapse infections. The circum-
sporozoite protein (CSP) is the major protein present on the
surface of sporozoites and is involved in hepatocyte binding and
invasion and as such is the lead vaccine candidate for malaria.
Presence of CSP on hypnozoites [6] makes it an attractive target
against both the sporozoite, and intrahepatic parasites. We have
designed and produced a vaccine based on the CSP of P. vivax
and demonstrated its antigenicity and immunogenicity [7] [8].
Rodents serve as a platform for the initial screening of malaria
vaccine candidates. However, non-human primates, being closer
to humans, are more suitable models to assess vaccines. A limited
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number of studies have been performed to analyze immunoge-
nicity, and even fewer to assess the efficacy, of candidate vaccines
for P. vivax in non-human primates. In the late 1980s and early
1990s studies were performed with recombinant P. vivax CS
proteins produced in yeast [9] and E. coli (WRAIR-SKB), which
gave little to no protection in immunized Saimiri monkeys [10].
Subsequently, multiple antigen constructs were used to develop
epitope-based vaccines using the vivax repeat motif. Protection
was observed in Saimiri monkeys [11] [12], but the lack of a
control group makes it difficult to conclusively interpret the data in
these studies. An Aotus monkey model was used to assess
immunogenicity of CS multiple antigen peptides (MAP) and long
synthetic peptides (LSP) and cells from immunized monkeys were
used to delineate T-cell epitopes on the protein [13] [14]. No
challenge studies were performed with the MAP or LSP
immunized monkeys to correlate the immunogenicity to protec-
tion.
In this study, we evaluated the immunogenicity and protective
efficacy of VMP001, a soluble P. vivax CSP-based vaccine, co-
formulated with a TLR-9 agonist and a water-in-oil emulsion.
Immunized A. nancymaae monkeys demonstrated high antibody
titers and high efficacy following challenge with P. vivax
sporozoites. Vaccine efficacy was shown to be associated with
antibodies to the repeat region of P. vivax CSP. To our
knowledge, this is the first report of an efficacy study of a
recombinant CSP-based vaccine in Aotus nancymaae monkeys,
and the first to conclusively correlate this protection to antibodies




The vaccine antigen, designated Vivax Malaria Protein 001
(VMP001), is based on the P. vivax CSP and has been described
previously [7,8]. Briefly, the gene encoding a chimeric central
repeat region containing the nonameric repeat motifs from both
VK210 (nine copies) and VK247 (one copy) parasites and flanked
by the N- and C-terminal regions of the P. vivax CSP was cloned
into a plasmid under a T5 promoter, expressed in Escherichia coli,
and purified under cGMP. The purified vaccine antigen did not
have detectable endotoxin, both by an in vitro assay, as well as by
in vivo pyrogenicity testing in rabbits [8].
P. falciparum Liver Stage Antigen 1 (PfLSA-1), kindly provided
by Dr. David Lanar [15], was used as an unrelated malaria
antigen for immunizing the control group of animals. Recombi-
nant proteins encoding the N-terminal and C-terminal regions of
P. vivax CSP were produced in E. coli for use as plate antigens in
humoral assays. A 36-mer peptide representing four copies of the
classical Type 1 repeat motif was used to detect antibodies to this
repeat region.
Ethics statement
The research using non-human primates (Aotus nancymaae
and Aotus lemuirinus grisiemembra) reported in this manuscript
was conducted under animal protocol number 1588BARMONB
and was approved by the Institutional Animal Care and Use
Committee (IACUC) of the Centers for Disease Control and
Prevention. The non-human primate (NHP) research was
conducted in compliance with the Animal Welfare Act and other
U. S. federal government statutes and regulations relating to
animals and research involving animals All NHP research
adhered to the principles stated in the Guide for the Care and
Use of Laboratory Animals, National Research Council. The
New World monkeys used in this study were either captive bred
or imported for research from Peru under a program adminis-
tered through PAHO and NIH for research purposes and were
socially pair-housed in appropriately spacious stainless steel cages
in a BSL2-facility at the CDC vivarium facilities in Atlanta,
Georgia, USA under controlled conditions of humidity, temper-
ature, and light (12-hour light/12-hour dark cycles). This facility
is fully accredited by the Association for the Assessment and
Accreditation of Laboratory Animal Care International and has
an approved OLAW Assurance #A4365-01. The animals were
provided with commercial high protein food biscuits and
supplemented with appropriate fresh vegetables, fruits and treats.
Drinking water was provided ad libitum. Enrichment was
provided in the form of hollow pieces of large tubing to simulate
tree trunk cavities, mirrors, food puzzles and perches. Animals
were monitored daily for health and discomfort. A large
experienced staff is available including full time veterinarians
and a pathologist. All steps were taken to ameliorate the welfare
and to avoid any suffering of the animals in accordance with the
recommendations of the Weatherall report for the use of
nonhuman primates in research. Major surgeries (splenectomy)
were performed with full anesthesia in aseptic surgical suites by
an experienced surgical veterinarian. Monkeys were not eutha-
nized during this research. Vivax malaria infections were treated
with standard antimalarial drugs; quinine, chloroquine and
primaquine as noted previously.
Immunizations and bleeds
Male and female monkeys were randomly assigned to three
groups of eight animals each. Two test groups received either
15 mg or 50 mg of VMP001 per immunization. A third group of
monkeys, which served as controls, was immunized with 50 mg P.
falciparum LSA-1. All antigens were formulated in Montanide
ISA 720 (Seppic, NJ) (antigen to adjuvant ratio of 30:70) plus
200 mg of CpG 10104 (Coley Pharma) per immunization. Animals
were immunized intramuscularly in the thigh muscles, alternating
legs for each immunization, with approximately 300 ml of each
Author Summary
Plasmodium vivax is responsible for causing malaria in
large parts of the globe, including regions with temperate
climates not suited for the transmission of other Plasmo-
dium species. In addition, P. vivax has the propensity to
form dormant forms, known as hypnozoites, that can
remain latent for weeks to months and reactive periodi-
cally to cause recurrent infections. Prevention of P. vivax
malaria, more than any other form, will require a vaccine-
based intervention due to limitations in treatment options.
To this end, we tested the efficacy in non-human primates,
of a vaccine based on circumsporozoite protein, a
preerythrocytic stage antigen, of P. vivax. Aotus monkeys
were immunized with clinical-grade antigen, combined
with two immunomodulators, and then challenged with P.
vivax sporozoites. Following challenge 66.7% of monkeys
were protected. Analysis of serum samples indicated that
protection was associated with antibodies to the central
repeat region of the molecule, and that protection was lost
upon waning of these antibodies. This is the first report
demonstrating that active immunization with a recombi-
nant protein can lead to complete protection in monkeys
following sporozoite challenge, while also demonstrating a
protective associate. Our data can help serve as a
benchmark for down-selection of future vaccine formula-
tions for P. vivax.
Protective efficacy of PvCSP in Aotus
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vaccine formulation on day 0, 28 and 114. Monkeys were bled two
weeks prior to immunization and at two-week intervals following
vaccinations for the collection of serum. Serum was separated by
centrifugation, aliquoted and frozen at 270uC until use.
Challenge
Sporozoites were isolated from salivary glands of Anopheles
dirus that were infected with the Brazil VII strain of P. vivax after
feeding on an infected A. lemurinus grisemembra monkey
Figure 1. Aotus nancymaae immunized with VMP001 generated antigen-specific antibodies that were boosted following each
immunization. Groups of 8 monkeys were immunized three times with either 15 mg (panel A) or 50 mg (panel B) of VMP001 formulated with 200 mg
CpG 10104 and Montanide ISA 720. Sera, drawn at two week intervals, were tested for presence of antibodies to VMP001. Antibody titers waned over
time, but were boosted with each immunization. Titers are defined as serum dilution that gives an OD414 of 1.0. Each symbol represents an individual
monkey. Some time points have less than eight data points due to the unavailibility of serum sample at that time point. Horizontal bars represent the
median titer for each group at the given time point.
doi:10.1371/journal.pntd.0003268.g001
Protective efficacy of PvCSP in Aotus
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(Barnwell et al. manuscript in preparation). The Brazil VII strain
of P. vivax carries a type I (VK210) csp gene (J. Barnwell,
unpublished data). Each monkey was challenged intravenously
with 10,000 sporozoites six weeks after the third immunization.
Two to three days following sporozoite challenge all the monkeys
were splenectomized under general anesthesia and sterile operat-
ing conditions. Splenectomies were performed to allow for the
establishment of a synchronous blood stage infection resulting in a
more uniform, and shorter, prepatent period.
Blood stage parasitemia was monitored in thick and thin
Giemsa stained blood smears starting approximately 14 days post-
challenge. Monkeys that demonstrated patent blood stage
infection were treated with 50 mg/kg of quinine for seven days.
Parasitemia was monitored on a daily basis until the conclusion of
second phase of the study (described below).
Kaplan-Meier survival curves were generated for each group
individually, as well as for pooled (low- and high-dose) vaccinated
groups, and plotted as percentage of uninfected monkeys over time.
Survival curve comparisons were performed using Log-rank (Mantel-
Cox) test. Overall vaccine efficacy (VE) was calculated as 1-R6100,
where R = Iv/Ic i.e. the ratio of Incidence of malaria in vaccinated
group (Iv) to the Incidence of malaria in the control group (Ic).
At eight weeks post primary challenge all surviving monkeys
were rechallenged intravenoulsy with a higher dose of 15,000 P.
vivax Brazil VII sporozoites. Monkeys that demonstrated patent
blood infection were treated with quinine as above.
ELISAs
Sera from monkeys were tested for the presence of CSP
antibodies following immunization. Immulon 2HB plates
(Dynatech, VA) were coated with 0.4 mg/ml VMP001, N- and
C-terminal regions of P. vivax CSP or 1 mg/ml of Type 1
peptide. Sera from a selected time point were also screened
against PfLSA1 to determine if the control group generated
antibodies against the transgene, and to ensure that there was
no cross reactivity between the control and vaccine groups.
Plates were blocked, incubated with serially diluted serum,
followed by 1:6000 dilution of a custom prepared goat anti-
Aotus IgG (CDC, Atlanta) labeled with horseradish peroxidase
(HRP). The reaction was developed with ABTS and read after
60 min at A414. ELISA titers are defined as the serum dilution
that gives an optical density (OD414) of 1.0.
Statistical analysis
GraphPad Prism version 5.0 was used for statistical analysis.
Tests used for each analysis are mentioned along with the
corresponding data.
Results
Immunogenicity of VMP001 vaccine in Aotus – Analysis of
anti-VMP001 antibodies
Monkeys were immunized with either 15 mg (low dose) or 50 mg
(high dose) of VMP001formulated with Montanide ISA 720 in
combination with 200 mg of CpG 10104, a TLR-9 agonist. This
study was designed with an ultimate goal of assessing the efficacy
of the VMP001 vaccine formulation. Adjuvants are known to
induce innate immune responses which can affect the outcome of a
challenge. Therefore, in order to rule out the role of non-specific
immune responses we immunized a group of monkeys with P.
Figure 2. Onset and magnitude of antibody response to VMP001 is similar in both the low (15 mg) and high (50 mg) dose groups. In
the presence of a strong adjuvant formulation the differences in anti-VMP001 titers between the two immunized groups were not stastically
significant (ns = p.0.05; 2-tailed Mann Whitney U test) at any timepoint. Data is represented as Box (25–75 percentile) and Whisker (minimum and
maximum) plot with horizontal line at the median value.
doi:10.1371/journal.pntd.0003268.g002
Protective efficacy of PvCSP in Aotus
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falciparum LSA-1 that served as an unrelated malaria antigen,
formulated in adjuvant. Monkeys were immunized three times,
with a one month interval between the 1st and 2nd immunization,
and a three month interval between the 2nd and 3rd immuniza-
tions. Animals were monitored following each immunization and
no reactogenicity or adverse events were observed. None of the
control monkeys that received PfLSA-1 generated any antibodies
against VMP001 following immunization, however, robust anti-
PfLSA1responses were detected in this group, while none of the
VMP001 immunized sera showed any anti-PfLSA1 reactivity
(data not shown). Anti-VMP001 antibodies were detected in all
monkeys immunized with VMP001 two weeks following the 1st
immunization (Figure 1). The median titers at 2 weeks post 1st
immunization were 14,581 and 67,695 for the low and high dose
Figure 3. Protective efficacy of VMP001 in Aotus monkeys challenged intravenously with P. vivax Brazil VII strain post primary and
rechallenge. Monkeys were immunized with either 15 mg or 50 mg of VMP001. Control monkeys were immunized with 50 mg of P. falciparum LSA-1
(PfLSA-1). All antigens were formulated with Montanide ISA 720 and CpG 10104. Kaplan-Meier survival curves represent percentage of uninfected
monkeys over time. Vaccine Efficacy was calculated as a ratio between the vaccinated and control groups (see results). 3A. Six weeks following the
third immunization, all monkeys were challenged intravenously with 10,000 P. vivax Brazil VII parasites. 3B. Eight weeks after the primary challenge,
monkeys were rechallenged with 15,000 P. vivax Brazil VII parasites.
doi:10.1371/journal.pntd.0003268.g003
Protective efficacy of PvCSP in Aotus
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groups, respectively. These titers were boosted significantly at 2
weeks post 2nd immunization for both the low dose (144,302;
p = .02) and high dose (198,024; p = .02) groups. Antibody titers
declined over time and the titers were significantly lower in both
immunized groups at 12 weeks after the 2nd immunization
compared to the peak titers obtained two weeks after the 2nd
immunization (p = .0006 and .015 for the low and high dose
groups, respectively). Titers showed a boost following the 3rd
immunization and peaked 4 weeks post 3rd immunization. There
was a significant difference between the titers at 12 weeks post 2nd
immunization (28,940) and 4 weeks post 3rd immunization
(140,367; p = 0.006) for the low dose group and the high dose
group (78,163 at 12 weeks post 2nd immunization and 291,622 at 4
weeks post-3rd immunization; p = .005). The peak titers post the
2nd and 3rd immunizations were not significantly different
(Figure 1).
The antibody titers for both the low and high dose groups were
similar at 2 weeks post each immunization (Figure 2). The median
titers ranged from a low of 14,581 at 2weeks post 1st immunization
for the low dose group, to a high of 198,024 for the high dose group
at 2 weeks post 2nd immunization. There were no statistical
differences in antibody titers between the groups at each time point
indicating that a strong adjuvant overcomes antigen dose effects.
Efficacy of VMP001 following intravenous challenge with
P. vivax Brazil VII parasites
Following intravenous inoculation of sporozoites, six of the eight
(75%) PfLSA-1 control monkeys became parasitemic, with a tight
pre-patent period ranging from day 14 to 18 post-challenge
(Figure 3A). In fact, five of the six infected monkeys had
demonstrated patent infection by day 16. The remaining monkey
became positive on day 18. Six of the eight monkeys in each of the
two vaccinated groups did not demonstrate patent infection. In
both the low and high dose groups 25% monkeys in each group
(2/8) became parasitemic with a prepatent period (day 17 and 28
for the low dose group; day 16 and 17 for the high dose group) that
was delayed in one animal compared to the controls. The median
prepatent period for the control group was 15.5 days, 22.5 days for
the low dose group and 16.5 days for the high dose group. Total
vaccine efficacy, calculated by comparing the ratio of infected
monkeys in the vaccinated vs. the control group, for each group
was 66.7%; and the p values, based on the Mantel-Cox Log-rank
test, for the time to parasitemia were .02 and .03 for the low and
high dose groups respectively.
Following treatment, all surviving monkeys were rechallenged
intravenously eight weeks post primary challenge with a higher
dose of 15,000 P. vivax Brazil VII sporozoites. This allowed for an
Figure 4. Infection with P. vivax Brazil VII sporozoites induces antibodies to VMP001. Control monkeys immunized with PfLSA-1 did not
generate antibodies against P. vivax (denoted as ‘‘pre challenge’’ in the figure). Following challenge with P. vivax sporozoites, the control monkeys
developed anti-P. vivax CSP antibodies, as assessed by ELISA reactivity to VMP001, that were significantly boosted following rechallenge (2-tailed
Mann-Whitney U test). Data is represented as Box (25–75 percentile) and Whisker (minimum and maximum) plot with horizontal line at the median
value.
doi:10.1371/journal.pntd.0003268.g004
Protective efficacy of PvCSP in Aotus
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approximately two-week interval between the clearance of any
primary infections before the rechallenge. Seven of seven control
monkeys became parasitemic between days 11 and 15 (Median
day 13) (Figure 3B). Six of six rechallenged monkeys in the high
dose group became parasitemic between days 12 and 22 (Median
day 14.5) and seven of eight of the low dose group became
parasitemic between day 12 and 18 (Median day 13.5). One
monkey in the low dose group did not become parasitemic during
the 33 day post-rechallenge observation period.
Induction of anti-VMP001 antibodies following challenge
with P. vivax sporozoites
As expected, the control animals, immunized with an unrelated
malaria antigen, PfLSA-1, did not induce antibodies to VMP001
(Figure 4) after the 3rd immunization. However, following primary
challenge, these animals generated antibodies to CSP, as
demonstrated by the presence of antibodies to VMP001 (Median
titer: 797). The titers were boosted approximately 10-fold
following rechallenge to a median titer of 7,670. The differences
between the prechallenge and post-challenge anti-PvCSP
(VMP001) titers in the PfLSA-1 group were statistically significant
(Figure 4). Since the prechallenge anti-VMP001 titers in the
vaccinated monkeys were already high, the differences in titers
post-challenge were not significant.
Immunogenicity of VMP001-antibody fine-specificity
analysis
Serum from immunized monkeys was further analyzed to assess
the breadth of antibody responses generated. At 4 weeks post 3rd
immunization (2 weeks pre-challenge) all monkeys demonstrated
presence of antibodies to the N-, Central Repeat as well as the C-
terminal region of P. vivax CSP. As with VMP001 (Median titers
of 140,367 and 291,622 for the low and high dose groups
respectively) there was no significant difference between the
antibody titers against the N-term (Median 7,277 vs. 22,188), Type
1 repeat peptide (Median 66,120 vs. 25,297) and C-term regions
(Median 77,111 vs. 179,947).
Association between anti-Type 1 antibody levels and
vaccine efficacy
The data was reanalyzed by pooling the protected (n = 12) and
non-protected (n = 4) monkeys from both the high and low dose
groups (Figure 5). There were no statistical differences between the
VMP001 (Median 214,659 vs. 156,247), N-term (Median 14,979
vs. 11,952) and C-term (Median 116,291 vs. 202,126) titers. The
titers to the Type 1 repeat peptide were significantly different
between the protected (Median 97,841) and non-protected
(Median 21,517) groups (p = 0.03; 2-tailed Mann-Whitney U test),
indicating that high anti-repeat antibodies may be a correlate of
protection. This is in accordance with data from P. falciparum
vaccine studies where anti-repeat antibodies have been shown to
be the strongest correlate of protection in humans [16].
As stated earlier, all but one of the vaccinated monkeys that
were protected following primary challenge (Figure 6A) lost their
protection upon rechallenge (Figure 6B). Nevertheless, when data
from the low- and high-dose groups were combined following
rechallenge and compared to the controls, there was still a
significant difference between the immunized and control groups
(p = 0.036) (Figure 6B). In comparison, following primary chal-
lenge the combined vaccinated groups had a p-value of 0.004
compared to the controls (Figure 6A).
We therefore compared the antibody titers in the prechal-
lenge sera from the monkeys that were protected prior to the
primary challenge to the titers in sera from those that were not
protected following rechallenge. Sera were drawn two weeks
before the primary-, or re-challenge. Here too, the only
significant differences were found between the anti-repeat
antibodies. As shown in Figure 6C the median anti-Type 1
repeat antibody titer in the protected monkeys was 97,841 at the
time of primary challenge compared to 14,822 (p = 0.02) in the
monkeys that were not protected following rechallenge. Thus,
the loss of protection in the previously protected monkeys could
be attributed to waning of the anti-repeat antibodies. Antibodies
to VMP001 also declined (Median 214,569 vs. 97, 296) but the
decrease was not statistically significant. There was no
association between antibody titers and time to patency in the
monkeys that became parasitemic.
Discussion
Due to financial, logistical, and scientific challenges, efforts to
develop vaccines for P. vivax have been disproportionately slower
compared to that for P. falciparum. In addition to the limited
number of preclinical studies in non-human primates that we
describe above, a recent review by Reyes-Sandoval and Bachman
[17] highlights the meager clinical portfolio of P. vivax vaccines
and the current status of vivax research and funding. In sharp
contrast to P. falciparum, so far, only one efficacy study has been
conducted in humans (clinical trials registration number
NCT01157897, Bennett et. al. in preparation). There is a need
to test products to down-select candidate(s) that can be advanced
to the clinic.
Towards this end, we produced a recombinant CSP-based
vaccine and assessed its immunogenicity in rhesus monkeys using
two different TLR4 agonists as adjuvants. In a study using a
synthetic TLR4 agonist, glucopyranosyl lipid A (GLA), formulated
in oil (GLA-SE), we demonstrated the safety and immunogenicity
of VMP001. The vaccine induced potent humoral responses
directed to the different regions of the molecule, and a cellular
response predominantly directed to the C-terminal region of the
protein [18]. In another study, rhesus monkeys were immunized
with soluble recombinant protein (VMP001), as well as its
particulate counterpart CSV-S,S which is a fusion between
VMP001 and the hepatitis B surface antigen to compare the
immunogenicity of the two formulations in AS01, an adjuvant
approved for human use [19]. Both the soluble and particulate
vaccines induced strong humoral and cellular immune responses,
but with some qualitative and quantitative differences between the
two formulations.
Figure 5. Protected monkeys from both the low- and high dose groups had significantly higher anti-repeat antibodies compared to
the non-protected monkeys. Pre-primary challenge sera from immunized monkeys from the low (15 mg) and high (50 mg) dose groups were
pooled from the protected (n = 12) and non-protected (n = 4) groups. Antibody reactivity between the protected and non-protected groups were
similar for VMP001, N- and C-terminal regions. However, anti-repeat antibodies were significantly different between the protected and non-protected
groups (p = 0.034, 2-tailed Mann Whitney U test). Data is represented as Box (25–75 percentile) and Whisker (minimum and maximum) plot with
horizontal line at the median value. Data also represented in a tabular form to demonstrate correlation bewteen protected and non-protected
groups.
doi:10.1371/journal.pntd.0003268.g005
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Figure 6. Loss of protective efficacy following rechallenge could be attributed to a drop in anti-repeat antibody titers. Kaplan-Meier
survival curves were generated by pooling data from the low (15 mg) and high (50 mg) dose groups (from Figure 3), and the combined VMP001
immunized group was compared to the control group. 6A. Following primary challenge, 12 of 16 immunized monkeys and 2 of 8 control monkeys
remained uninfected, resulting in a calculated vaccine efficay of 66.7% (p = 0.004). 6B. Following rechallenge, one immunized monkey remained
uninfected and several others had a delay compared to the controls (p = .04). 6C. Sera drawn two weeks prior to the first challenge from protected
monkeys (n = 12) had significantly higher anti-repeat antibody titers compared to sera drawn pre-rechallenge from the non-protected monkeys
(n = 13); p = 0.02 (2-taled Mann Whitney U-test). Titers indicate serum dilution that gives an OD414 of 1.0. Each dot represents an individual monkey.
Horizontal bar represents the median titer for each group.
doi:10.1371/journal.pntd.0003268.g006
Protective efficacy of PvCSP in Aotus
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The present study was undertaken to test the immunogenicity,
as well as efficacy, of VMP001 in Aotus monkeys. We immunized
monkeys with two different doses of antigen formulated in
Montanide ISA 720 and CpG 10104. Montanide ISA 720 is a
water-in-oil emulsion constituted of a nonmineral metabolizable
oil and a mannide monooleate surfactant [20]. CpG 10104 is a B-
class 24-mer synthetic oligonucleotide with a fully phosphorothio-
ate backbone containing 5 CpG motifs (Coley Pharma). These
unmethylated CpG DNA motifs are recognized by mammalian
TLR9 and are known to activate dendritic cells, macrophages and
B cells [21]. Both Montanide ISA 720 and CpG have been used in
clinical studies in humans with malaria antigens (www.clinicatrials.
gov) and thus, have a possible path forward for the clinical
evaluation of vaccine candidates. Therefore, we chose to evaluate
our vaccine in the presence of these adjuvants to take advantage of
their synergistic roles in inducing a functionally-relevant immune
response. Due to the possible effect of the innate immune
responses induced by this combination of adjuvants on the
outcome of a parasite challenge, we included a control arm in
which the monkeys were injected with the adjuvant formulated
with an unrelated P. falciparum antigen that does not exist in P.
vivax. The final vaccine efficacy was estimated by comparing it to
the outcome of the control group. Due to the fact that 25% of the
control monkeys did not become parasitemic, our calculated
vaccine efficacy for both the low and high dose groups singly, and
in combination, following the primary challenge was 66.7% with a
total of 12 out of 16 immunized monkeys remaining free of blood
stage parasites. Both the low- and high-dose groups induced robust
immune responses to the whole recombinant protein (VMP001),
as well as the N-term, repeat- and C-term regions of the protein.
However, only anti-repeat antibodies showed a statistical associ-
ation with protection. The twelve protected monkeys had
statistically significant antibody response that was 4.5-fold higher
compared to the response in the non-protected monkeys. In
contrast, the protected and non-protected monkeys had differences
of 1.7-fold, or less, in anti-VMP001, N- and C-term antibody
titers. While similar comparisons with the various components (the
entire immunogen, or the C-term region) have not been published
for RTS,S the only subunit malaria vaccine to show consistent
protection in humans, evaluation of anti-repeat antibodies has
been shown to be a strong correlate of protection [16]. In a
previous study, passive transfer of a mouse monoclonal antibody
directed against the repeat region of the P. vivax CSP was shown
to protect 4/6 monkeys [22]. However, immunization with
PvCSP recombinant proteins failed to induce protective anti-
repeat antibodies [22] [10].
The strength of our protective correlate to the anti-repeat titers
is further bolstered by the results of the rechallenge experiment.
Since only one monkey stayed protected after the rechallenge, it
was not possible to compare the protected vs. non-protected
groups post-rechallenge. Therefore, we compared the anti-Type 1
repeat antibody titers in the monkeys that were protected post-
primary challenge vs. those that were not protected post-
rechallenge. The antibody titers showed a significant decline from
a median of 97,841 pre-primary challenge to 14,822 pre-
rechallenge. This 6.6-fold drop in titers was statistically significant
(p = .02) and explains the loss of protection in the previously
protected monkeys.
We would be remiss in not stating, as pointed out by one of the
reviewers, that T cell responses were not evaluated in this study. In
addition, this study was not designed to test effectiveness against in
situ hypnozoites and it is possible that this vaccine may or may not
be effective against established hypnozoites, and thus may need to
be reformulated and associated with other antigens.
In summary, we demonstrate VMP001 vaccine-induced pro-
tection in the presence of strong immunomodulators, Montanide
ISA 720 and a TLR9 agonist. The presence of one, or both, of
these components may have caused a qualitative shift in the
immune response to drive the production of high-titers of anti-
repeat antibodies to a level that resulted in protection. The results
of this study—using the nonhuman primate model of the P. vivax
Brazil VII strain in A. nancymaae—can help serve as a benchmark
for down-selection of adjuvant formulations in future studies with
the current vaccine antigen, or while designing new antigens to
serve as a vaccine.
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